The estimated Net Worth of Svetlana Lucas is at least 11.4 千$ dollars as of 26 April 2023. Ms. Lucas owns over 6,000 units of Atyr Pharma Inc stock worth over 11,400$ and over the last 5 years she sold LIFE stock worth over 0$. In addition, she makes 0$ as Independent Director at Atyr Pharma Inc.
Sign up
Ms. Lucas LIFE stock SEC Form 4 insiders trading
Svetlana has made over 1 trades of the Atyr Pharma Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently she exercised 6,000 units of LIFE stock worth 11,400$ on 26 April 2023.
The largest trade she's ever made was exercising 6,000 units of Atyr Pharma Inc stock on 26 April 2023 worth over 11,400$. On average, Svetlana trades about 857 units every 0 days since 2019. As of 26 April 2023 she still owns at least 6,000 units of Atyr Pharma Inc stock.
You can see the complete history of Ms. Lucas stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Svetlana Lucas biography
Svetlana Lucas Ph.D. serves as Independent Director of the Company. Dr. Svetlana Lucas has 18 years of experience in strategy, commercialization, and business development leadership, with a particular expertise in oncology and immunology. She currently serves as a Chief Business Officer at a newly formed biotechnology company. Prior to her current role, she served as Senior Vice President, Business Development at Tizona Therapeutics, Inc. (Tizona), a clinical stage immunotherapy company, where she was responsible for the company’s business development strategy and transactions, including global strategic collaboration with AbbVie Inc. Before joining Tizona, Dr. Lucas was Head of Oncology and Inflammation at Amgen Inc. (Amgen), where she oversaw business development activities, including Amgen’s strategic cancer immunotherapy research collaboration and licensing agreement with Kite Pharma, and collaborated with Amgen Ventures on several investments in oncology and inflammation. Dr. Lucas joined Amgen following the acquisition of Onyx Pharmaceuticals, Inc. (Onyx), where she spearheaded the company’s oncology partnering strategy and due diligence of new opportunities. Prior to Onyx, she held positions of increasing responsibility in strategy, business development and strategic marketing at Amgen, PDL BioPharma/Facet Biotech (acquired by AbbVie), and XOMA Corporation. She began her career as a strategy consultant in the Life Sciences practice of McKinsey & Company, Inc. Dr. Lucas received her Ph.D. in Molecular Biology and Biochemistry from California Institute of Technology, and an undergraduate degree in Biology from Moscow State University.
What's Svetlana Lucas's mailing address?
Svetlana's mailing address filed with the SEC is C/O ATYR PHARMA, INC., 10240 SORRENTO VALLEY ROAD, SUITE 300, SAN DIEGO, CA, 92121.
Insiders trading at Atyr Pharma Inc
Over the last 16 years, insiders at Atyr Pharma Inc have traded over 27,288,922$ worth of Atyr Pharma Inc stock and bought 966,653 units worth 5,761,237$ . The most active insiders traders include James C Blair、Gregory T Lucier、Craig J Mundie. On average, Atyr Pharma Inc executives and independent directors trade stock every 22 days with the average trade being worth of 34,257$. The most recent stock trade was executed by Jill Marie Broadfoot on 31 May 2024, trading 5,000 units of LIFE stock currently worth 8,950$.
What does Atyr Pharma Inc do?
atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation
What does Atyr Pharma Inc's logo look like?
Complete history of Ms. Lucas stock trades at Atyr Pharma Inc
Atyr Pharma Inc executives and stock owners
Atyr Pharma Inc executives and other stock owners filed with the SEC include:
-
Dr. Sanjay S. Shukla,
Pres, CEO & Director -
Sanjay Shukla,
President, Chief Executive Officer, Director -
Jill M. Broadfoot,
Chief Financial Officer -
Nancy E. Denyes Krueger,
Gen. Counsel & Corp. Sec. -
Jill Broadfoot,
Chief Financial Officer -
Nancy Denyes,
General Counsel and Corporate Secretary -
Paul Schimmel,
Independent Director -
John Clarke,
Independent Chairman of the Board -
Svetlana Lucas,
Independent Director -
Jeffrey Hatfield,
Independent Director -
Jane Gross,
Independent Director -
Timothy Coughlin,
Independent Director -
Dr. David J. King,
Scientific Consultant -
Dr. Melissa A. Ashlock,
Sr. Advisor -
Dr. Ying J. Buechler,
Exec. Director of Biologics Devel. & Manufacturing -
Peter Villiger,
VP of Corp. Devel. -
Ashlee Dunston,
Director of Investor Relations & Corp. Communications -
Xiang-Lei Yang Ph.D.,
Founder -
Donald W Grimm,
Director -
Arnold J Levine,
Director -
Ronald Asbury Andrews,
President, Medical Sciences -
George F Jr Adam,
Director -
David C Uprichard,
Director -
Gregory T Lucier,
CEO -
Kelli Richard,
Chief Accounting Officer -
Bradley G Lorimier,
Director -
Peter Michael Leddy,
SVP, Human Resources -
Balakrishnan S Iyer,
Director -
Raymond V Dittamore,
Director -
Per A Peterson,
Director -
Craig J Mundie,
Director -
Mark P Stevenson,
President & COO -
Ora H. Pescovitz,
Director -
Ronald A Matricaria,
Director -
John A Cottingham,
Chief Legal Officer -
David F Hoffmeister,
Chief Financial Officer -
Claude Benchimol,
SVP, Advanced Genomic Systems -
William H Longfield,
Director -
Nicolas Barthelemy,
President, Cell Systems -
John L Miller,
President - Genetic Systems -
Mark Sean O'donnell,
SVP, Global Operations & Serv. -
Peter Dansky,
Pres, Molecular Biology Sys -
Bernd Brust,
Pres, Commercial Operations -
Paul David Grossman,
SVP, Corporate Strategy & Dev. -
W Ann Reynolds,
Director -
Joseph C Beery,
SVP, Chief Information Officer -
William S Shanahan,
Director -
James C Blair,
Director -
John Mendlein,
Director -
Sara Zaknoen,